newsfilter
← Latest News
ACCESS Newswire·

EyeGate Pharma to Proceed with PE Pivotal Study

EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that based on feedback from a meeting with the U.S. Food and Drug Administration ("FDA"), EyeGate can move forward with the filing of an IDE for a punctate epitheliopathies ("PE") pivotal study.